Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Canada-US Trade Talks Gain Momentum Ahead of Aug. 19 Tariff Deadline 
S&P 500 Hits Record High as Soft Inflation Data Eases Fed Rate Hike Fears 
Trump Imposes New Tariffs on Drone Imports Over US Security Concerns 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Ford to Move Some Lincoln Production From China to U.S. in 2030 
Japan Government Backs Earlier BOJ Rate Hike as Inflation Pressures Build 
US Dollar Slips as Softer PPI Data Eases Fed Rate Hike Expectations 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
Asian Currencies Steady Ahead of US CPI as Oil Prices Rise 
Add as a preferred source on Google
GSK, a British pharmaceutical and biotech firm that was formerly known as Glaxo Smith Kline plc, announced that it had hired Julie Brown to be its new chief financial officer. The company said on Monday, Sept. 26, that the executive would formally join GSK next week.
According to Sky News, the move to recruit Brown is a strategy to form an all-female team of executives. It was reported that the newly-recruited CFO was poached by GSK from the Burberry Group PLC fashion company.
Brown will be replacing Iain Mackay, who is set to retire. He has been serving as GSK’s finance chief since 2019. The formation of an all-female team is very rare in the business, but the company is aiming for this with the recruitment of Brown.
Reuters reported that Brown is set to step down in April 2023 from Burberry after serving for more than five years as its CFO. She is a 60-year-old British woman who started working at the said fashion house in 2017. Prior to this, she worked at Smith & Nephew's medical device products manufacturing firm.
She also held an executive job role in AstraZeneca as interim group CFO and was appointed to senior roles at some of GSK’s rival companies. In addition, she was a non-executive director of Roche Holding Swiss healthcare group, but she is likely to step down after accepting the CFO role at GSK.
“I want to thank Iain for all he’s done for GSK, and for his leadership and support to our people. He has played a very significant role to help deliver the reshaping of GSK and to improve our operating and financial performance,” GSK’s chief executive officer, Emma Walmsley, said in a press release. “I am absolutely delighted that Julie will be joining the leadership team as his successor. Julie is a highly experienced CFO with a tremendous understanding of the biopharma sector.”
The CEO added, “We also share a strong passion for people development, diversity, inclusion and sustainability. I am looking forward to working together to deliver progress for patients, shareholders and our people.”
